Phase III trial comparing 3–6 months of adjuvant FOLFOX4/XELOX in stage II–III colon cancer: safety and compliance in the TOSCA trial

Sara Lonardi, Alberto Sobrero, Gerardo Rosati et al.|Annals of Oncology|2016

Cited by 56